Invasive facial fungal infections: Orofacial soft-tissue infiltration in immunocompromised patients
Peter Jun, MD; Matthew Russell, MD; Ivan El-Sayed, MD; William Dillon, MD; and Christine Glastonbury, MD Invasive facial fungal infections affect the orofacial soft tissues in immunocompromised patients and can cause significant morbidity and mortality. Primary infection occurs from direct inoculation of the skin surface, while secondary infection occurs from extension from an adjacent sinonasal process. The imaging features of secondary infection are similar to acute fulminant invasive fungal sinusitis with infiltration of the orofacial soft tissues in combination with sinonasal disease. However, primary infection can occur in the absence of sinonasal disease, making diagnosis challenging. We present two cases, one of primary and one of secondary invasive facial fungal infection. Careful scrutiny of the orofacial soft tissues in immunocompromised patients is necessary to detect invasive facial fungal infections so that appropriate surgical and medical therapies can maximize patient outcomes.
held, and multiple antifungal agents, granulocyte-colony stimulating factor, and granulocyte infusions were administered. The patient remained neutropenic and died from sepsis 10 days later.
Discussion
Orofacial soft-tissue infiltration in an immunocompromised patient is an independent radiologic sign of invasive facial fungal infections. The normal orofacial soft tissues are composed of well-defined facial muscles separated by intact planes of fat. This relationship is maintained in nearly all normal patients, even in the presence of inflammatory sinus disease (1) . In cases of invasive facial fungal infections, these planes are disrupted when fungal species disseminate intravascularly, causing an infectious vasculitis with consequent soft-tissue hemorrhage, thrombosis, and infarction (2) .
Secondary invasive facial fungal infections are an extension of acute fulminant invasive fungal sinusitis and therefore share similar imaging features. Nasal-cavity opacification has been described as the earliest sign of invasive fungal disease; however, this finding can be extremely subtle and can also be seen with benign inflammatory sinusitis (3, 4) . The presence of nonenhancing mucosa adds specificity, which pathologically correlates with necrotic mucosa (5, 6) . From the nasal cavity, disease spreads to the maxillary sinus and orofacial soft tissues. Bone erosion and intraorbital and intracranial invasion are late findings indicative of advanced disease (7, 8) .
Primary invasive facial fungal infections begin in the orofacial soft tissues and are not expected to have sinonasal involvement until later in their course. The pathogenesis of primary invasive facial fungal infections is likely similar to primary disease outside of the head and neck and has been well described in immunocompromised patients, particularly pediatric patients with hematologic malignancies (9) . Iatrogenic trauma to the protective dermal layers by adhesives and catheters allows fungus access to the subcutaneous tissues, allowing for dissemination (10, 11) . In our case of primary disease, direct inoculation may have occurred from the adhesives used to secure a feeding tube. The absence of clinical or imaging findings of sinonasal disease highlights the need to raise the possibility of an invasive fungal infection even when only orofacial soft-tissue infiltration is seen on imaging.
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Orofacial soft-tissue infiltration can occur in conditions aside from invasive fungal infections. Trauma, dental disease, bacterial cellulitis, and (more recently) dermal fillers can mimic the imaging appearance of invasive facial fungal infections. Dermal fillers are unique in that they are frequently used to treat retroviral lipodystrophy in HIV patients, a subset at high risk for invasive fungal disease (12) . Hyaluronic acid is most commonly used, but other agents include collagen, silicone, and polytetrafluoroethylene. The CT and MRI appearance of these agents vary, but a transient inflammatory reaction is common, with occasional occurrences of a severe chronic inflammatory response with diffuse swelling and enhancement of the orofacial soft tissues (13, 14) . Knowledge of the appropriate clinical history is necessary to avoid this potential pitfall.
The treatment of invasive facial fungal infections is similar to that for other invasive fungal diseases and is based on a three-pronged approach: antifungal therapy, surgical debridement, and immune recovery. Antifungal therapy and surgical debridement limit spread and disease burden, but ultimately immune recovery is the best predictor of survival (5) . Early recognition of the imaging signs of primary and secondary invasive facial fungal infections allows for appropriate diagnostic testing and treatment, thereby offering the patient the best chances for recovery.
